Latest News

Longevity Science Is Advancing. Can Clinical Care Keep Up?

Longevity Science Is Advancing. Can Clinical Care Keep Up?

The search to live longer is not new, but we are no longer looking for a hypothetical fountain of youth. Over the past few decades, research into metabolic health, longevity biomarkers, and more has led to longevity breakthroughs that open up new possibilities for...

read more

Latest News

Weekly News Roundup | 12 October 2026

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

read more
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....

read more
Viatris Pacira Acquisition: What the $1.65bn Deal Buys

Viatris Pacira Acquisition: What the $1.65bn Deal Buys

The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...

read more
GLP-1 Therapy: More Than Numbers on a Scale

GLP-1 Therapy: More Than Numbers on a Scale

The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Weekly News Roundup | 13 July 2026

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

read more
Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

read more
Clinical Trials Roundup | 10 July 2026

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

read more
FDA Drug Approval Decisions to Watch: July and August 2026

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

read more
Atacicept FDA Approval: Trutakna Cleared for IgAN

Atacicept FDA Approval: Trutakna Cleared for IgAN

The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...

read more
AI Trust in Healthcare Starts with the People in the Room

AI Trust in Healthcare Starts with the People in the Room

Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...

read more
The Regulatory Window for AI in Pharmacovigilance Is Open

The Regulatory Window for AI in Pharmacovigilance Is Open

In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...

read more
Weekly News Roundup | 13 July 2026

Weekly News Roundup | 13 July 2026

Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...

read more
Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

Medicare GLP-1 Bridge: Who Qualifies and Who Does Not

The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...

read more
Clinical Trials Roundup | 10 July 2026

Clinical Trials Roundup | 10 July 2026

Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...

read more
FDA Drug Approval Decisions to Watch: July and August 2026

FDA Drug Approval Decisions to Watch: July and August 2026

The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...

read more
Atacicept FDA Approval: Trutakna Cleared for IgAN

Atacicept FDA Approval: Trutakna Cleared for IgAN

The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...

read more
AI Trust in Healthcare Starts with the People in the Room

AI Trust in Healthcare Starts with the People in the Room

Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...

read more
The Regulatory Window for AI in Pharmacovigilance Is Open

The Regulatory Window for AI in Pharmacovigilance Is Open

In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

When Months Become Days: AI’s Edge in Patient Engagement

When Months Become Days: AI’s Edge in Patient Engagement

Every therapy that reaches a patient first has to clear a quieter hurdle that rarely makes headlines: finding enough of the right people to test it. That hurdle is where most clinical programs stumble. Roughly 80% of clinical trials fail to meet their enrollment...

read more
Workforce Capability Standardization in Medical Affairs

Workforce Capability Standardization in Medical Affairs

For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...

read more
Weekly News Roundup | 06 July 2026

Weekly News Roundup | 06 July 2026

Life science news 6 July 2026: the FDA expands the world’s first CRISPR gene therapy to children as young as two, Ipsen commits up to $1.75 billion for a late-stage blood cancer drug, and two first-in-class FDA approvals reshape the cell therapy landscape in a busy...

read more
Atacicept IgA Nephropathy: FDA Decision Due 7 July

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...

read more
Clinical Trials Roundup | 03 July 2026

Clinical Trials Roundup | 03 July 2026

Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...

read more
FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

read more
Beyond Animal Models: iPSC Assays Unlock the Human Brain

Beyond Animal Models: iPSC Assays Unlock the Human Brain

For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...

read more

Further News

Twin B7-H3 ADC Wins in Seoul Leave the UK Route Unresolved

Two B7-H3 ADC readouts landed in the same Seoul session on 13 September 2026. Both reported a survival win in relapsed small cell lung cancer. Both trials ran entirely in China. Neither dataset, on its own, is a filing package for the FDA, the EMA or the MHRA. Two...

Collagen Bioinks: A New Standard for 3D-Printed Tissue Constructs

Collagen bioinks have to satisfy two very different demands. They need to behave predictably during printing, and once the printing stops they must also provide an environment in which cells can organise and begin behaving like tissue. However, it’s typically the...

Autoimmune Serology Redefined: Deep B-Cell Depletion and IgG Blockade

In October 2025, the FDA approved an anti-CD20 monoclonal antibody for adults with active lupus nephritis receiving standard therapy. In the phase 3 REGENCY trial, 46.4% of patients receiving B-cell depletion plus standard therapy achieved a complete renal response at...

Radial Immunodiffusion Protocol and Troubleshooting: Why RID Still Matters

Abstract Radial immunodiffusion (RID) can look almost outdated beside ELISA, multiplex assays, and automated analytical platforms. Yet that apparent simplicity may be exactly why the method still deserves attention. RID offers a direct, visually interpretable way to...

Weekly News Roundup | 14 September 2026

Life science news 14 September 2026: two US approvals for rare diseases, a landmark antibody-drug conjugate readout, and two UK moves on pharmacy access and AI oversight. Scholar Rock’s Isembyld won FDA approval, described by the agency as the first SMA therapy to...

Cabozantinib Salt Form Wins FDA Approval Past Malate Patents

A new cabozantinib salt form has cleared the US Food and Drug Administration. Handa Oncology announced on 11 September 2026 that the agency had granted final approval to OMCAZIO (cabozantinib) capsules. The product sits outside the patent estate Exelixis has spent...

Lenacapavir NHS Access Stalls as NICE Rejects Twice-Yearly PrEP

NICE draft guidance rejects lenacapavir for HIV pre-exposure prophylaxis on cost-effectiveness grounds, leaving lenacapavir NHS access to a November committee and an unpublished UK price.

    The GLP-1 Divide: Who Gets the Best Weight-Loss Drugs, and Who Pays for It

    A patient arrived on my ward recently with a story I have heard so many times it no longer surprises me. Her blood sugar had crept back into the danger zone, her blood pressure was climbing, and the weight she had lost over the previous year was almost all back. The...

    Clinical Trials Roundup | 11 Sept 2026

    Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...

    Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To

    Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...

    Partial Clinical Hold Lands on Opakalim Before SK Deal Closes

    The FDA imposed a partial clinical hold on Biohaven’s opakalim on 4 September 2026, nine days after SK Biopharmaceuticals licensed the Kv7 asset.

      The Other Half of Innovation

      What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.